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Abstract 
Purpose: To develop and validate a dissolution test method for tablets containing 80 mg of drotaverine 
hydrochloride (DRT) and 250 mg of mefenamic acid (MEF). 
Methods: Sink conditions, drug stability and specificity in different dissolution media were tested to 
optimize a dissolution test method using a USP paddle type dissolution test apparatus set at a speed of 
50 rpm. The dissolution medium consisted of 900 ml of phosphate buffer (pH 6.8) containing 0.25% w/v 
cetrimide at 37 ± 0.5 oC and 45 min time-point. To determine both drugs simultaneously, a first 
derivative UV spectrophotometric method was developed and validated. Drug release was analyzed by 
first derivative UV method at 253.8 nm and 304 nm for DRT and MEF respectively. The dissolution 
method was validated as per ICH guidelines. 
Results: The two brands each showed 98% of drug release for both drugs when the developed 
dissolution method was used. The regression plot was linear in the concentration range 4 - 24 µg/mL for 
each of the drugs and regression coefficient (r2) was greater than 0.999 for each drug. Relative 
standard deviation (% RSD) for precision and accuracy of proposed method was < 2.  
Conclusion: The proposed dissolution method is simple, cost-effective, precise, accurate and specific. 
It can be successfully employed in routine quality control of DRT and MEF combination tablets.     
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Drotaverine hydrochloride (DRT, Figure 1A), 
chemically 6,7,3',4'-Tetraethoxy-1-benzal-1,2,3,4 
-tetrahydroisoquinoline hydrochloride, is an 
analogue of papaverine with smooth muscle 
relaxant properties. Mefenamic acid (MEF, 
Figure 1B), chemically, 2-[(2, 3-Dimethylphenyl) 
amino] benzoic acid, is an agent which exert its 
analgesic, anti-inflammatory, and antipyretic 
properties by inhibition of cyclooxygenase [1-6].  
The combined dosage form of DRT and MEF is 
therapeutically used for uterine irritability, as well 
as primary and secondary dysmenorrhoea. 
 
Dissolution testing of poorly soluble compounds 
in immediate release solid dosage forms 
presents several challenges. Single dissolution 
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method for the analysis of combined dosage 
forms is preferred for simplification of quality 
control testing [7-13]. However, development of a 
single dissolution method for DRT and MEF is 
practically challenging due to the pH dependent 













   A                                        B 
 
Figure 1: Chemical structures of (A) drotaverine 
hydrochloride (DRT)and (B) mefenamic acid (MEF) 
 
Presently, assay of DRT is not described in any 
pharmacopoeia and there is no specification for 
its dissolution test, but a dissolution medium, tris 
buffer (pH 9.0) containing 1 %w/v sodium lauryl 
sulphate, is recommended for MEF. This 
dissolution medium is not suitable for in vitro 
dissolution test of immediate release dosage 
forms since the pH of gastro-intestinal tract is not 
anywhere near 9.0. To the best of our 
knowledge, no single in vitro dissolution test has 
been reported for DRT and MEF in a combined 
tablet dosage form. Therefore, the objective of 
the present work was to develop and validate a 
single dissolution test method for DRT and MEF 
in a combined tablet dosage form using first 






DRT and MEF were obtained as a gifts from 
Aurobindo Pharmaceutical and Wan Bary Ltd, 
Hyderabad, India. Hydrochloric acid, methanol, 
ortho-phosphoric acid, potassium dihydrogen 
orthophosphate, sodium hydroxide and sodium 
chloride were purchased from SD Fine 
Chemicals Ltd, Mumbai, India; sodium lauryl 
sulfate (SLS), Tween 80 and cetrimide were 
purchased from Himedia Ltd, Mumbai, India. 
Double distilled water was used throughout the 
study. DRT and MEF combination tablet 
formulations - Doverin-M (Intas Pharmaceuticals 
Ltd, India) and Drofem (FDC Ltd, India) - were 




Electrolab-TDT-08L dissolution test apparatus, 
double beam 1800 UV-Visible spectrophotometer 
(Shimadzu, Japan), analytical balance 
(Shimadzu AUX 220, Japan), orbital shaker bath 
(Bio-Technics, India), pH meter (Elico, 
Hyderabad)  and ultrasonic cleaner (Sonica, 
Italy) were used for the study. 
 
Selection of wavelength 
 
Standard solutions of DRT and MEF were diluted 
appropriately with phosphate buffer (pH 6.8) to 
obtain a solution containing DRT (12 µg/mL) and 
MEF (12 µg/mL). The spectra of these diluted 
solutions were scanned in the spectral region of 
200 to 400 nm using phosphate buffer pH 6.8 as 
blank. The zero-order spectra of DRT and MEF 
were transformed to corresponding first-




First-order derivative spectra of DRT (12 µg/mL) 
and MEF (12 µg/ mL) were overlapped. The 
zero-crossing point (ZCP) values of MEF at 
which the DRT showed some derivative 
response were recorded. The wavelength, 253.8 
nm, was selected for the quantification of DRT 
(where the derivative response for MEF was 
zero) while 304.0 nm was selected for the 
quantification of MEF (where the derivative 
response for DRT was zero). The optimized 
wavelengths of 253.8 nm and 304 nm for DRT 
and MEF, respectively were confirmed by 
checking the derivative absorbance of various 
concentrations of both drugs in the range of 4 - 
24 µg/mL.[14]. 
 
Dissolution test conditions 
 
Dissolution testing of combined DRT and MEF 
tablet formulation (Doverin-M) was performed in 
a paddle type USP tablet dissolution apparatus, 
in 900 mL of various buffer and surfactant media 
at 50 rpm and 37 ± 0.5 °C for 45 min. Aliquots of 
5.0 mL were withdrawn at 5 min interval up to 45 
min, and replaced with an equal volume of fresh 
medium to maintain sink conditions. At the end of 
the test, the withdrawn samples were filtered, 
diluted with phosphate buffer pH 6.8 and 
quantified by the developed and validated 
spectrophotometric derivative method (n = 3). 
The amount of dissolved drugs was computed 
from the respective calibration curves and then 
plotted against time.  
 
The media in which highest drug release 
occurred for Doverin-M, and this medium was 
chosen for in vitro dissolution studies in 
DROFEM.  
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The dissolution method was validated as per ICH 
guidelines. The parameters assessed were 




Specificity is the ability of the method to 
accurately measure a compound in the presence 
of other components such as impurities, 
degradation products and matrix components. 
The specificity of the proposed method was 
evaluated through the analysis of a placebo 
solution, which it was prepared with the common 
excipients (lactose, starch, microcrystalline 
cellulose, magnesium stearate and talc) of the 
pharmaceutical formulation. Thus, the mixture of 
component inert was prepared in their usual 
concentration employed in tablets 
(concentrations were determined based in 
Handbook of pharmaceutical Excipients and 
calculated for medium weight of content). The 
developed method was applied to in order to 
check if any component of the formulation could 
generate a response or a read with absorption 




Appropriate aliquots of standard stock solutions 
of DRT (100 µg/mL)  and MEF (100 µg/ mL) 
were taken in two different sets of 10 mL 
volumetric flasks and diluted up to the mark with 
phosphate buffer (pH 6.8) to obtain  final 
concentrations of  4 - 24 µg /mL  for both drugs. 
First-derivative spectra were recorded using the 
prepared solutions against phosphate buffer (pH 
6.8) as blank. The values of the first-derivative 
absorbance for DRT and MEF were obtained 
using six different concentrations by measuring 
each concentration against solvent blank at the 
chosen wavelength 253.8 nm and 304 nm for 
DRT and MEF, respectively. The values of first-
derivative absorbance were plotted against 





The precision of the method was determined by 
repeatability (intra-day) and reproducibility (inter-
day precision). It was evaluated based on the 
relative standard deviation (% RSD) [18]. The 
intra- and inter-day precision were assessed 
after subjecting six tablets to the dissolution test 
conditions, on the same day and on three 




Accuracy was evaluated by adding known 
amounts of the reference substance to the 
placebo sample in the dissolution medium at 80 
%, 100 % and 120 % of the nominal assay value 
of DRT and MEF. The accuracy was calculated 





The dissolution data of the two formulations were 
subjected to statistical analysis using Student’s t-
test by Prism 4.0 software, and differences 





Development of dissolution test method 
 
Selection of dissolution test method was based 
on screening studies using USP apparatus 2 at a 
paddle speed 50 rpm: operating conditions are 
listed in Table 1.Selection of a dissolution 
medium to accommodate adequate solubility and 
stability of both DRT and MEF was critical for the 
selected dissolution method. Several compendia 
dissolution media were screened; these include 
various media - buffer (pH 1.2 to 9.0), surfactant 
and buffer/surfactant. The addition of surfactants 
to the buffer solution was also investigated 
[15,16], Cummulative DRT and MEF release 
(Figure 2) in phosphate buffer (pH 6.8) 
containing 0.25 %w/v cetrimide was 98.8 and 
101.3 %, respectively, from Doverin-M tablets. 
Therefore, the selected dissolution test 
conditions were: USP apparatus 2 at paddle 
speed 50 rpm in a medium of phosphate buffer 
(pH 6.8) containing 0.25 %w/v cetrimide. 
Dissolution studies on Drofem tablets were 
performed at these dissolution test conditions. 
These results, shown in Figure 2, reveal that 
99.01 and 101.16 % of DRT and MEF were 
released, respectively, from Drofem tablets in the 
optimized medium. Statistical analysis of the 
dissolution profile data for the two formulations 
indicate that the profiles were similar (tcal = 4.0 
and 0.15 for DRT and MEF, respectively, which 




The derivative spectra of placebo, DRT and MEF 
in the dissolution medium, shown in Figure 3, 
reveal that there was no interference from the 
excipients in the tablets (placebo) with derivative 
response of either of drugs (DRT and MEF) at 
their respective analytical wavelengths of 253.8 
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and 304 nm, respectively. Hence, the method is 
specific [17]. 
 
Table 1: Dissolution efficiency in various dissolution 
media based on paddle method, stirring rate of 50 
rpm, temperature of 37 0C ± 0.5 and time point of 45 
min  
 
DEa ± SD (n = 3)  Dissolution media 
DRT MEF 
Doverin-M  (Brand-I)   
Distilled water 38.79±1.89 17.19±0.19 
Hydrochloric acid 62.93±0.39 4.99±0.42 
Tris buffer, pH 4.0 87.60±0.38 4.86±0.01 
Acetate buffer, pH 4.6 81.82±0.53 4.86±0.36 
Phosphate buffer, pH 6.8 48.61±0.19 22.00±1.19 
Phosphate buffer, pH 7.4 36.44±0.74 42.62±0.37 
Tris buffer, pH 9.0 18.59±0.66 88.75±0.42 
0.25%w/v cetrimide 95.46±1.05 87.14±0.37 
0.25%w/v  SLS* 35.32±0.68 11.54±0.42 
0.25%w/v Tween 80 35.06±0.40 25.66±0.21 
Phosphate buffer, pH 6.8 + 
0.25%w/v cetrimide 
98.84±0.42 101.1±0.76 
Phosphate buffer, pH -6.8 
+0.25% w/v SLS 
62.09±0.67 21.92±0.02 
phosphate buffer, pH -6.8 
+0.25%v/v Tween 80 
34.87±0.39 24.99±0.222 
Drofem (Brand II)   
Phosphate buffer (pH 6.8) 
+ 0.25%w/v cetrimide 
99.01±0.34 100.16±0.37 
 
*Sodium lauryl sulphate; aDissolution efficiency 
 
 
   
 
Figure 2: Dissolution profiles of DRT () and MEF 




Figure 3: First order spectra of placebo (a), drota-
verine hydrochloride (b) and mefenamic acid(c)   
Linearity  
 
Linearity plots for DRT and MEF are shown in 
Figure 4. The results reveal that both DRT and 
MEF show a linear relationship in the 
concentration range of 4 - 24 µg/mL for both 
drugs, with regression coefficient (r2) of 0.999 for 
both DRT and MEF. 
 
 
Figure 4: First order spectrum of linearity range of (a) 




The % relative standard deviation values were 
found to be less than 2 for intra and inter day 
precision studies and there is no significant 
difference was observed between intra and inter 
day values, which indicates that the proposed 
method was precise and reproducible.  Results 




The results are reported in Table 3. The %RSD 
values obtained for DRT and MEF were < 2, 
indicating that the method is accurate for its 




In order to develop single dissolution method for 
simultaneous quantification of the DRT and MEF, 
initial trials were performed with the objective to 
accommodate adequate solubility and stability of 
both drugs. Sink conditions, stability of the drugs 
and specificity in different dissolution media were 
tested to optimize a dissolution test. The 
screening results showed that the dissolution 
rate of DRT is higher in pH 4.0 tris buffer than in 
the other buffers and also that if the dissolution 
rate of MEF increased with increasing medium 
pH, then a single pH buffer would be unsuitable 
for the method chosen. Both drugs exhibited 
higher dissolution rate in 0.25 %w/v cetrimide 
than in 0.25 %w/v sodium lauryl sulphate and
Anumolu et al 




Table 2: Precision data for the proposed method 
 
DRT MEF  
Product Intra-day(%) Inter-day (%) Intra-day (%) Inter-day (%) 
 Mean±SD %RSD Mean±SD %RSD Mean±SD %RSD Mean±SD %RSD 
Doverin 99.06±0.47 0.476 100.20±1.25 1.247 100.79±0.21 0.208 99.98±0.99 0.990 
Drofem 99.29±0.20 0.203 99.10±0.98 0.988 100.9±0.137 0.135 98.89±1.25 1.264 
 
Table 3: Results for accuracy for the proposed method 
 
Amount of reference (µg/ml) Analyte % level of recovery Added Recovered %Recovery %RSD 
DRT 80 7.11 7.02 98.73 1.10 
 100 8.80 8.65 98.29 0.89 
 120 10.60 10.62 100.18 1.24 
MEF 80 22.20 22.00 99.09 1.02 
 100 27.70 27.80 100.03 0.98 
 120 33.30 33.20 99.69 0.85 
 
0.25 %v/v Tween 80, due to electrostatic 
interaction between anionic drugs with cationic 
surfactants (cetrimide). Thus, the in vitro 
dissolution of DRT and MEF was significantly 
dependent on the type of surfactant used 
Finally, 900 mL of phosphate buffer (pH 6.8) 
containing 0.25 %w/v cetrimide as dissolution 
media, USP paddle type dissolution apparatus at 
a speed of 50 rpm and temperature of 37 ± 0.50 
C, and 45-min time point were selected as the 
optimum dissolution test conditions. Acidic drugs 
might dissociate into an anionic form before 
solubilizing in micelles, which were formed by the 
cationic surfactant at pH 6.8. This anionic form of 
acidic drug could have interacted with the 
cationic surfactant, which will facilitate its 
partitioning into micelles, and increase its 
solubility and further dissolution when compared 
to that of the media containing non-ionic and 
anionic surfactants. The pH of the dissolution 
medium (pH 6.8) is within the range of GI-tract 
pH levels and low concentration of surfactant 
(0.25 % w/v cetrimide). This medium is 
convenient and suitable for the study of the 
dissolution profiles of DRT and MEF when 
combined in a tablet dosage form.   
 
Generally, for simplification of quality control 
testing, single dissolution methods are preferred 
for the analysis of combined drug in a dosage 
form. Therefore, our goal was to develop a cost-
effective, simple and specific single dissolution 
method for the simultaneous quantification of 
both drugs (DRT and MEF). To evaluate both 
drugs simultaneously, a first derivative UV 
method was developed and validated. The 
method is selective for the simultaneous 
determination of DRT and MEF since no 
interfering peaks appeared near the absorption 
peaks of the compounds of interest. The 
developed dissolution method was successfully 
employed for two different brands of tablets. The 
data obtained also indicate that the method is 
accurate and precise within the desired range. 
Student’s t-test analysis indicates that the 
dissolution profiles of the two test formulations 




A dissolution test for the simultaneous 
determination of DRT and MEF in tablets has 
been successfully developed and validated 
according to ICH guidelines. The proposed 
dissolution test conditions should enhance 
laboratory efficiency and is specific, cost-
effective, accurate and precise.  Thus, the 
proposed dissolution method can be used in the 
routine quality control analysis of DRT and MEF 
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